NCT04909853 - Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

October 7, 2021

Study Completion Date

October 7, 2021

Conditions

Renal Impairment

Interventions

DRUG

PF-07321332/ritonavir

PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19

Trial Locations (5)

Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Miami

University of Miami Division of Clinical Pharmacology, Miami

Genesis Clinical Research, LLC, Tampa

Prism Research LLC dba Nucleus Network, Saint Paul

Orange County Research Center, Tustin